Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Cellosaurus-based systematic survey of sarcoma cell lines identifies critical gaps in public availability and priorities for future cell line development.

Human cell·2026
Same author

A soft tissue mass around the arteries after pancreatectomy: the association with local recurrence and the impact of neoadjuvant radiotherapy in pancreatic ductal adenocarcinoma.

Surgery today·2026
Same author

Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Distinct epidemiology and treatment outcomes between skeletal and extraskeletal Ewing sarcoma in Japan: a population-based study.

Japanese journal of clinical oncology·2026
Same author

Simultaneous Pancreas and Kidney Transplantation in a Patient With Congenital Hemophilia A: A rare Case Report and Management Insights.

Transplantation proceedings·2026
Same author

Impact of preoperative skeletal muscle mass on the healing time of postoperative pancreatic fistula after pancreaticoduodenectomy.

Langenbeck's archives of surgery·2026

Related Experiment Video

Updated: Sep 18, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Pharmacokinomic Profiling Using Patient-Derived Cell Lines Predicts Sensitivity to Imatinib in Dermatofibrosarcoma

Rei Noguchi1, Takuya Ono1, Kazuki Sasaki2,3

  • 1Division of Rare Cancer Research, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

Cells
|June 25, 2025
PubMed
Summary

Predictive biomarkers for imatinib response in dermatofibrosarcoma protuberans (DFSP) were identified. Kinase activity profiling in patient-derived cell lines revealed FER, ITK, and VEGFR1 as potential markers for imatinib sensitivity.

Keywords:
biomarkerdermatofibrosarcoma protuberansdrug screeningimatinibkinase activitypatient-derived cell linepharmacokinomicssarcoma

More Related Videos

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.6K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Related Experiment Videos

Last Updated: Sep 18, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.6K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Dermatofibrosarcoma protuberans (DFSP) is a rare skin sarcoma.
  • Imatinib is a standard treatment, but resistance occurs in 10-50% of patients.
  • Predictive biomarkers are needed to guide DFSP treatment selection.

Purpose of the Study:

  • To identify predictive biomarkers for imatinib response in DFSP.
  • To explore a pharmacogenomic approach using patient-derived cell lines.
  • To discover novel therapeutic targets for imatinib-resistant DFSP.

Main Methods:

  • Established and utilized four patient-derived DFSP cell lines.
  • Analyzed tyrosine kinase activity using PamChip arrays with and without imatinib.
  • Conducted drug screening with 60 FDA-approved tyrosine kinase inhibitors.

Main Results:

  • Increased PDGFRB activity correlated with imatinib sensitivity.
  • Imatinib sensitivity was associated with the activity of FER, ITK, and VEGFR1 kinases.
  • These kinases show potential as predictive biomarkers for imatinib response.

Conclusions:

  • A pharmacogenomic approach can identify predictive biomarkers for imatinib response in DFSP.
  • FER, ITK, and VEGFR1 activity may predict sensitivity or resistance to imatinib.
  • This strategy can help personalize DFSP treatment and guide alternative therapies.